Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
Saved in:
Main Authors: | , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
2011
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1516-84842011000200012 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1516-848420110002000122011-06-13Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaConchon,MonikaFreitas,Carla Maria Boquimpani de MouraRego,Maria Aparecida do CarmoBraga Junior,José Wilson Ramos Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy Drug toxicity Drug interactions Gastrointestinal tract/drug effects Drug resistance, neoplasm Pyrimidines Interferonalpha/administration & dosage Piperazines/therapeutic use Clinical Trial Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.33 n.2 20112011-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012en10.5581/1516-8484.20110034 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Conchon,Monika Freitas,Carla Maria Boquimpani de Moura Rego,Maria Aparecida do Carmo Braga Junior,José Wilson Ramos |
spellingShingle |
Conchon,Monika Freitas,Carla Maria Boquimpani de Moura Rego,Maria Aparecida do Carmo Braga Junior,José Wilson Ramos Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
author_facet |
Conchon,Monika Freitas,Carla Maria Boquimpani de Moura Rego,Maria Aparecida do Carmo Braga Junior,José Wilson Ramos |
author_sort |
Conchon,Monika |
title |
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
title_short |
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
title_full |
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
title_fullStr |
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
title_full_unstemmed |
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
title_sort |
dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
description |
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects. |
publisher |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publishDate |
2011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012 |
work_keys_str_mv |
AT conchonmonika dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT freitascarlamariaboquimpanidemoura dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT regomariaaparecidadocarmo dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT bragajuniorjosewilsonramos dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia |
_version_ |
1756423528032239616 |